additional navigation


You are here:

  • Home
  • Research & development

Research & development

AOP Orphan is a research-oriented pharmaceutical company and invests a high amount of its yearly turnover in the Research and Development of drugs. AOP Orphan primarily focuses on rare diseases, otherwise referred to as orphan diseases. The European Union states that a disease can be classified as rare if only 5 out of 10,000 people are affected by it.

As a fully integrated pharmaceutical company, AOP Orphan's areas of activities cover the research, development, production, marketing and distribution of medication.

How does AOP Orphan research and develop?

AOP Orphan’s in-house research team covers all key aspects of product development including preclinical research, toxicology, pharmaceutical development, clinical development, regulatory affairs, quality management, pharmacovigilance and project management.

continue to How does AOP Orphan research and develop?

Development Phases

Before a drug is released for sale, it needs to be tested in clinical trials for tolerability, safety and efficacy. Such trials are subject to strict, internationally recognized guidelines and must be carried out using defined procedures.

continue to Development Phases

Research Areas

AOP Orphan is actively involved in a range of research projects focusing on rare diseases.

continue to Research Areas

Current Studies

The current focus of research activities is on myeloproliferative and cardiovascular diseases.

continue to Current Studies

Cooperation Agreements

AOP Orphan can draw on a global network of cooperation agreements which cover the areas of research, production and distribution in equal measure.

continue to Cooperation Agreements

AOP Orphan Contact

AOP Orphan Germany

AOP Orphan worldwide

Products & Area of treatment